Purchase this article with an account.
Yutaka Kato, Akira Ojima, Ryutaro Tomita, Tetsuju Sekiryu; Six-month result of anti-VEGF therapy for macular edema secondary to branch retinal vein occlusion.. Invest. Ophthalmol. Vis. Sci. 2018;59(9):4282.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate visual outcome and frequency of injection in treating macular edema secondary to branch retinal vein occlusion (BRVO-ME) with ranibizumab.
A prospective case series. Twenty five eyes of 25 patients with newly diagnosed BRVO-ME were evaluated; 8 males and 17 females, mean age 71 years old. All patients underwent ophthalmic examination including measurement of the best corrected visual acuity (BCVA) and evaluation of the fovea using optical coherence tomography (OCT) (Cirrus OCT, Carl-Zeiss, Germany). All eyes were treated with intravitreal injection of ranibizumab (IVR) as the initial treatment and received as needed reinjection during 6 months followed-up period. Retreatment criteria was central subfield thickness (CST) exceeded 300 μm. Patients were randomly assigned to 2 groups; IVR group in which patients received IVR monotherapy, and IVR+PC group in which patients received laser photocoagulation (PC) if IVR was needed at month 3 in addition the same therapy as IVR group. Number of injections and changes in BCVA and CST were evaluated.
In all 25 eyes, 14 eyes were assigned to IVR group, and 11 eyes were assigned to IVR+PC group. At the baseline, mean logMAR of IVR group and IVR+PC group were 0.52±0.36, 0.44±0.28, and mean CST of each group were 518±149, 487±153µm, respectively. There were no significant differences between 2 groups in logMAR (p=0.26) and CST (p=0.30). In 11 eyes of IVR+PC group, 4 eyes received PC at month 3. At month 6, mean logMAR of IVR group and IVR+PC group improved to 0.17±0.23 (p<0.01), 0.08±0.18 (p<0.01), and mean CST of each group improved to 308±97 (p<0.01), 311±95µm (p<0.01), respectively. There were no significant differences between the groups in logMAR (p=0.13) and CST (p=0.46). Numbers of IVR were 3.4 times in IVR group and 3.0 times in IVR+PC group.
As needed dosing of ranibizumab was effective for BRVO-ME during 6 months. PC did not contribute for further improvement of BCVA or reduction of IVR.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.
This PDF is available to Subscribers Only